People - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

People

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 2

People on the move in February 2007.

Greenwich, CT (Feb. 20)Aptuit, Inc. ( http://www.aptuit.com/) announced a series of promotions and shifting of responsibility in its senior management team. These changes include: Frank J. Wright becomes vice-chairman, responsible for external value creation and global integration activities and also has been nominated to the company's board of managers. Scott L. Houlton becomes chief operating officer, with responsibility for scientific operations, business process Improvement, human resources, clinical operations, and capital development. Michael J. Butler, president, scientific operations, will take responsibility for Aptuit's technology and innovation investment activities, including research and development. And Robert G. Burford, managing director, has assumed additional responsibility as chairman of the management committee of Aptuit Consulting.

InformexUSA, San Francisco (Feb. 14)—Halocarbon Products Corporation (River Edge, NJ, http://www.halocarbon.com/) named Mary Ellen Rubinstein marketing manager with responsibility for three product lines: inhalation anesthetics; fluorochemicals; and oils, greases, and waxes. Halocarbon is a producer of specialty fluorochemicals.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here